NAD+ (injectable)
naturally occurring coenzyme (a dinucleotide, not a peptide)
Also called: thymosin beta-4 fragment, Ac-LKKTETQ, TB4 fragment, thymosin beta-4 (Tβ4)
Thymosin beta-4 is a natural 43-amino-acid protein involved in cell movement and tissue repair. 'TB-500' is a trade name for a synthetic version, and anti-doping chemists have identified a short acetylated 7-amino-acid fragment (Ac-LKKTETQ) in TB-500 products, so what a given vial contains can vary.
It has a reputation as a whole-body recovery peptide for soft-tissue injuries and is frequently paired with BPC-157. It also has a long history in horse racing doping cases.
Human evidence: none. No published human trials of injected TB-500 or its fragment; the only human data concern full-length thymosin beta-4 drug candidates (mainly topical or eye-drop formulations).
S2.3 Growth Factors and Growth Factor Modulators. 'Thymosin-β4 and its derivatives, e.g. TB-500' is named; prohibited at all times.
High. Validated detection methods exist. USA Powerlifting tests against the WADA list (https://www.usapowerlifting.com/tue/); other tested federations generally use WADA-style lists.
Not FDA-approved. FDA had TB-500 (thymosin beta-4 fragment) in Category 2 of the interim 503A list. It was removed from Category 2 on April 15, 2026 (still not eligible for compounding). On July 23, 2026 the Pharmacy Compounding Advisory Committee voted 8-6 to recommend it for the 503A bulks list. No final FDA action has been found as of Oct 1, 2026.
As of 2026-10-01.
S2.3 Growth Factors and Growth Factor Modulators. 'Thymosin-β4 and its derivatives, e.g. TB-500' is named; prohibited at all times. High. Validated detection methods exist. USA Powerlifting tests against the WADA list (https://www.usapowerlifting.com/tue/); other tested federations generally use WADA-style lists.
Not FDA-approved. FDA had TB-500 (thymosin beta-4 fragment) in Category 2 of the interim 503A list. It was removed from Category 2 on April 15, 2026 (still not eligible for compounding). On July 23, 2026 the Pharmacy Compounding Advisory Committee voted 8-6 to recommend it for the 503A bulks list. No final FDA action has been found as of Oct 1, 2026.
None. No published human trials of injected TB-500 or its fragment; the only human data concern full-length thymosin beta-4 drug candidates (mainly topical or eye-drop formulations).
Research-use-only information file. Nothing here is medical advice or instructions for use. Not evaluated by the FDA. Talk to your doctor.
naturally occurring coenzyme (a dinucleotide, not a peptide)
synthetic 15-amino-acid peptide fragment derived from a protein found in gastric juice